Dr Carsten Thiel

Carsten is a visionary leader with a strong science-based background with PhD in Molecular Biology from Max-Planck Institute. Carsten’s career has been commercially focused in both public and private companies with the highlight of generating >4x IRR with the successful exit of EUSA Pharma.

His core expertise lies in turning businesses around, driving significant top and bottom-line growth, managing small and large teams, M&A activities and integration, building, restructuring and revitalizing capability. He has a demonstrable record of driving hyper-growth at iconic companies through innovation and operational excellence, and guiding diverse, cross-functional teams.

Most recently, Carsten built out the rare disease capabilities at EUSA Pharma, restructured the company as CEO. In 2022 the company was acquired by RECORDATI.

Carsten has been recognized as one of “The Top 25 Healthcare Technology CEOs of Europe for 2021”